Vicinitas Therapeutics Appoints Christian Hofmann, Ph.D., as Chief Executive Officer
Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today announced that Christian Hofmann, Ph.D., has been appointed as the company’s Chief Executive Officer and member of the board of directors.
- Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today announced that Christian Hofmann, Ph.D., has been appointed as the company’s Chief Executive Officer and member of the board of directors.
- Dr. Hofmann joins Vicinitas from Lycia Therapeutics, a biotechnology company focused on extracellular protein degradation, where he served as Chief Business Officer.
- Prior to Genentech, he held business development and portfolio management positions of increasing responsibility at several startups and Roche Diagnostics.
- “I believe that Vicinitas represents an enormous opportunity to help patients by targeting proteins previously considered undruggable, and I look forward to working alongside the company’s world class team.”